MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
1.350
+0.080
+6.30%
After Hours: 1.370 +0.02 +1.48% 17:27 02/06 EST
OPEN
1.300
PREV CLOSE
1.270
HIGH
1.410
LOW
1.283
VOLUME
526.79K
TURNOVER
--
52 WEEK HIGH
7.19
52 WEEK LOW
1.260
MARKET CAP
37.78M
P/E (TTM)
-0.2287
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JSPR last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at JSPR last week (0119-0123)?
Weekly Report · 01/26 09:45
Weekly Report: what happened at JSPR last week (0112-0116)?
Weekly Report · 01/19 09:49
Jasper Therapeutics initiated with a Buy at Rodman & Renshaw
TipRanks · 01/13 20:20
Jasper Therapeutics Showcases Briquilimab’s Potential in Targeted Mast Cell Depletion for Inflammatory Diseases
Reuters · 01/12 17:02
Weekly Report: what happened at JSPR last week (0105-0109)?
Weekly Report · 01/12 09:48
RBC Capital Keeps Their Hold Rating on Jasper Therapeutics (JSPR)
TipRanks · 01/09 12:17
Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
TipRanks · 01/08 17:55
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.